Business
Embla Medical hf: Interim Report Q3 2025
Embla Medical hf: Interim Report Q3 2025
About this update from Embla Medical Hf
COPENHAGEN, Denmark , Oct. 21, 2025 /PRNewswire/ -- Announcement no. 49/2025 Interim report Q3 2025 21 October 2025 Sveinn Sölvason, President and CEO, comments: "Sales in Q3 2025 amounted to USD 237 million, representing 11% reported growth, of which 7% was organic. Growth picked up in the third quarter as expected, driven by double-digit growth in Prosthetics & Neuro Orthotics. The solid momentum in EMEA continues and growth in Americas was strong following a soft start to the year, supported by our recently launched innovations such as Navii, Icon, and Pro-Flex Terra. Sales in our Bracing & Supports and Patient Care segments remained soft with flat sales in Bracing & Supports and modest growth in Patient Care. At the end of August, we closed the majority investment in Streifeneder ortho.production, which positions us as a full-range provider with opportunities to strengthen our presence in our key O&P markets and expand our offerings and reach in Emerging Markets. The EBITDA margin was strong at 22% in Q3 2025 and 21% for the first nine months of the year compared to 20% in the comparable period. In line with our performance recorded in the first nine months of 2025, our guidance for the full-year 2025 has been reiterated." Highlights Q3 2025 Other highlights 2025 Outlook * Potential impact from US trade tariffs continues to be an uncertain element to quantify given the frequent changes in the global tariff environment. Consequently, we deem it too speculative to quantify and guide an exact impact from potential tariffs on Embla Medical's financial results, but some absorption of tariffs is assumed in the guidance. Conference call details Embla Medical will host a conference call on October 21, 2025, at 9:00 CET / 7:00 GMT / 3:00 ET . To actively participate in the telephone conference, please use the dial-in details provided below: DK: +45 78 76 84 90 UK: +44 20 3769 6819 US: +1 646 787 0157 Participant access code: 274982 The webcast will be available through following link: Embla Medical Q3 2025 webcast Investor presentation Our updated Q3 2025 investor road show presentation can be downloaded from our IR website Link Further information Klaus Sindahl, Head of Investor Relations, [email protected] , +45 5363 0134 Embla Medical press releases by e-mail If you wish to receive Embla Medical press releases by e-mail, please register at http://www.emblamedical.com/investors About Embla Medical Embla Medical (Nasdaq Copenhagen: EMBLA) was founded in Reykjavik in 1971 with the mission to improve people's mobility. Embla Medical is home to several brands renowned for positively impacting people's health and well-being. They include Össur, a leading global provider of prosthetics and bracing and supports solutions; FIOR & GENTZ, an innovative developer of neuro orthotics; and College Park Industries, creators of custom-built prosthetic solutions. Embla Medical also provides patients with world-class care through a global network of Orthotic and Prosthetic (O&P) facilities. Embla Medical is committed to sustainable business practices and is signatory to the UN Global Compact, UN Women's Empowerment Principles, and contributes to the UN Sustainable Development Goals. The company's climate targets have been verified by the Science Based Targets initiative. Embla Medical operates globally and has more than 4,000 employees. www.emblamedical.com Embla Medical was formerly listed as Össur (OSSR) on Nasdaq Copenhagen until 8 April 2024. This information was brought to you by Cision http://news.cision.com https://news.cision.com/embla-medical-hf-/r/embla-medical-hf--interim-report-q3-2025,c4253370 The following files are available for download: View original content: https://www.prnewswire.co.uk/news-releases/embla-medical-hf-interim-report-q3-2025-302589824.html